Digital transformation, internationalization, innovation and sustainability – The newly elected board of directors endeavors to reinforce the association’s position as a platform for addressing the industry’s pressing issues. New structures will strengthen dialogue and communication.
Stuttgart, Germany, April 29, 2026. For more than twenty years Interessengemeinschaft Pharmabau 3000 e. V. (VIP3000) has supported the technological development of pharmaceutical production facilities and related specialist areas. The association brings together experts and pools the experience and ideas of leading companies, research institutes, suppliers, planners and higher education institutions.
Since the members’ meeting held in Dusslingen (district of Tübingen) last week, a new board of directors has been at the helm of the network. The members elected Stefan Göstl, Head of Life Sciences and Chemicals and Partner at Drees & Sommer, as President. Previously, he had served as the association's Vice President. Stefan Göstl is taking over the position held by Ralf Gegenbach with immediate effect. The latter did not seek re-election, but will retain his links to the association as Honorary President. Ralf Stahl, Managing Director at Kemmlit, was appointed as the new First Vice President, from his previous position as Coordinator. The newly elected board member Alexandra Reinhold-Fedler, who heads sales at Fischer Mess- und Regeltechnik GmbH will be responsible for coordination. The remaining directors of the board were confirmed in office.
New Structures for Key Sector Topics
Stefan Göstl, the association’s new President comments: “Technological progress, new regulatory requirements and an increasing focus on the future viability of buildings, production equipment and plant infrastructures are rapidly changing the demands placed on research and production facilities. We will consolidate VIP3000’s role as a hub for practical experience and dialogue between all stakeholders, facilitating the creation of innovative solutions within the ecosystem of our industry.” A key first step was the use of a newly introduced workstream format at the members’ meeting. In focus sessions, the participants discussed market development issues, shared their experience regarding compliance with the European Union Good Manufacturing Practice guidelines (EU GMP Annex I) on manufacturing sterile medicinal products, and exchanged their expertise.
Going forward, VIP3000 will organize its work into several workflows: market, regulatory matters, and technology und innovation form the core pillars in terms of content. The cross-sectional issues of sustainability and digital transformation are integrated into all areas.
Network Strengthens Dialogue within Life Sciences Sector
The meeting in Dusslingen marks a change in the board of directors, bringing clear content-related development. “The future of research, development and production real estate or facilities emerges where technology, architecture and science converge. We build bridges: VIP3000’s events for experts and network meetings promote the exchange of information within the industry. We aim to strengthen the sector’s overall position,“ Stefan Göstl points out. The newly elected board of directors will shape the association’s work over the next three years.
For more information on VIP3000, please visit the website.
